| CASE REPORT |
|
| Year : 2022 | Volume
: 11
| Issue : 4 | Page : 469-471 |
|
|
Tuberculosis treatment-related lichenoid drug eruptions
Zeynep Yegin Katran1, Ismet Bulut1, Aylin Babalık2
1 Department of Allergy and Immunology, University of Health Sciences, Süreyyapasa Training and Research Hospital, Istanbul, Turkey
2 Department of Chest Diseases, University of Health Sciences, Süreyyapasa Training and Research Hospital, Istanbul, Turkey
Correspondence Address:
Zeynep Yegin Katran
Department of Allergy and Immunology, University of Health Sciences, Süreyyapasa Training and Research Hospital, Istanbul
Turkey
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijmy.ijmy_151_22
|
|
|
Tuberculosis is one of the leading causes of death from infectious diseases in adults worldwide. Drug hypersensitivity in tuberculosis is an important problem affecting the treatment process. Although treatment is started with isoniazid, rifampicin, ethambutol, and pyrazinamide in drug-sensitive tuberculosis patients, it may not always be continued in this way. When hypersensitivity develops under antituberculosis treatment, type 4 hypersensitivity is the most common, and maculopapular drug eruption develops as a subgroup. Lichenoid drug eruption is very rare. We present our case who was diagnosed with pulmonary tuberculosis, who developed lichenoid drug eruption while receiving treatment, and whose treatment was completed by giving the new regimen with successful desensitization.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
